Ranbaxy Pharmaceuticals Inc., a wholly owned subsidiary of Ranbaxy Laboratories Ltd. (RLL), has launched authorized generic pioglitazone hydrochloride tablets in the U.S. market,  under an agreement with Takeda Pharmaceuticals U.S.A., Inc.  
 
Pioglitazone hydrochloride tablets is an oral antidiabetic agent that acts primarily by decreasing insulin resistance, presently distributed by Takeda Pharmaceuticals America, Inc. under the brand name Actos. The product is indicated for patients as an adjunct to diet and exercise to improve glycemic controls in adults with type 2 diabetes mellitus. Actos® generated total annualized sales of $2.7 billion in the U.S. (IMS – MAT June 2012).
 
Bill Winter, Vice President, Trade Sales and Distribution, North America, Ranbaxy said, “Ranbaxy is making available the full range of generic pioglitazone in 15 mg, 30 mg, and 45 mg tablets. The introduction of generic pioglitazone hydrochloride tablets is a significant and important addition to our portfolio of antidiabetic products in the U.S. The launch further complements our resolve to bring high quality, affordable generic medicines as early as possible to the U.S. healthcare system.”
 
Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India’s largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.